Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dose Selection of CAEL-101 in AL Amyloidosis
NCT04304144Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anselamimab in amyloid light chain amyloidosis, sponsored by Alexion Pharmaceuticals. Started Mar 2020; status: completed.
02
Drugs
anselamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04304144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304144.